Skip to Main Content

Author Details

Whitney B Pope
David Geffen School of Medicine, University of California los angeles
1992
167
56
PMIDPaper TitleJournal TitlePublished Year
35917833Artificial intelligence (AI)-based decision support improves reproducibility of tumor response assessment in neuro-oncology: An international multi-reader study.Neuro Oncol2023
35704275Amine-weighted chemical exchange saturation transfer magnetic resonance imaging in brain tumors.NMR Biomed2023
35917833Artificial intelligence (AI)-based decision support improves reproducibility of tumor response assessment in neuro-oncology: An international multi-reader study.Neuro Oncol2023
35704275Amine-weighted chemical exchange saturation transfer magnetic resonance imaging in brain tumors.NMR Biomed2023
34350525Characterization of cognitive function in survivors of diffuse gliomas using resting-state functional MRI (rs-fMRI).Brain Imaging Behav2022
35626127Diagnostic and Prognostic Value of pH- and Oxygen-Sensitive Magnetic Resonance Imaging in Glioma: A Retrospective Study.Cancers (Basel)2022
35371980Paradoxical Association Between Relative Cerebral Blood Volume Dynamics Following Chemoradiation and Increased Progression-Free Survival in Newly Diagnosed IDH Wild-Type MGMT Promoter Methylated Glioblastoma With Measurable Disease.Front Oncol2022
35736864Characterization of Cognitive Function in Survivors of Diffuse Gliomas Using Morphometric Correlation Networks.Tomography2022
36053452Relapse patterns and radiation dose exposure in IDH wild-type glioblastoma at first radiographic recurrence following chemoradiation.J Neurooncol2022
34350525Characterization of cognitive function in survivors of diffuse gliomas using resting-state functional MRI (rs-fMRI).Brain Imaging Behav2022
34865129Diffusion MRI is an early biomarker of overall survival benefit in IDH wild-type recurrent glioblastoma treated with immune checkpoint inhibitors.Neuro Oncol2022
34563433Imaging Advances for Central Nervous System Tumors.Hematol Oncol Clin North Am2022
35020109Radiomics for precision medicine in glioblastoma.J Neurooncol2022
35058510Visualization of tumor heterogeneity and prediction of isocitrate dehydrogenase mutation status for human gliomas using multiparametric physiologic and metabolic MRI.Sci Rep2022
35736864Characterization of Cognitive Function in Survivors of Diffuse Gliomas Using Morphometric Correlation Networks.Tomography2022
35371980Paradoxical Association Between Relative Cerebral Blood Volume Dynamics Following Chemoradiation and Increased Progression-Free Survival in Newly Diagnosed IDH Wild-Type MGMT Promoter Methylated Glioblastoma With Measurable Disease.Front Oncol2022
35626127Diagnostic and Prognostic Value of pH- and Oxygen-Sensitive Magnetic Resonance Imaging in Glioma: A Retrospective Study.Cancers (Basel)2022
36053452Relapse patterns and radiation dose exposure in IDH wild-type glioblastoma at first radiographic recurrence following chemoradiation.J Neurooncol2022
35058510Visualization of tumor heterogeneity and prediction of isocitrate dehydrogenase mutation status for human gliomas using multiparametric physiologic and metabolic MRI.Sci Rep2022
34865129Diffusion MRI is an early biomarker of overall survival benefit in IDH wild-type recurrent glioblastoma treated with immune checkpoint inhibitors.Neuro Oncol2022
35020109Radiomics for precision medicine in glioblastoma.J Neurooncol2022
34563433Imaging Advances for Central Nervous System Tumors.Hematol Oncol Clin North Am2022
32646876Voxelwise and Patientwise Correlation of <sup>18</sup>F-FDOPA PET, Relative Cerebral Blood Volume, and Apparent Diffusion Coefficient in Treatment-Naïve Diffuse Gliomas with Different Molecular Subtypes.J Nucl Med2021
33704629Preferential tumor localization in relation to <sup>18</sup>F-FDOPA uptake for lower-grade gliomas.J Neurooncol2021
34121166Worse prognosis for IDH wild-type diffuse gliomas with larger residual biological tumor burden.Ann Nucl Med2021
33691798Differentiating IDH status in human gliomas using machine learning and multiparametric MR/PET.Cancer Imaging2021
32646876Voxelwise and Patientwise Correlation of <sup>18</sup>F-FDOPA PET, Relative Cerebral Blood Volume, and Apparent Diffusion Coefficient in Treatment-Naïve Diffuse Gliomas with Different Molecular Subtypes.J Nucl Med2021
33359353Using non-invasive neuroimaging to enhance the care, well-being and experimental outcomes of laboratory non-human primates (monkeys).Neuroimage2021
33106922Relative oxygen extraction fraction (rOEF) MR imaging reveals higher hypoxia in human epidermal growth factor receptor (EGFR) amplified compared with non-amplified gliomas.Neuroradiology2021
33704629Preferential tumor localization in relation to <sup>18</sup>F-FDOPA uptake for lower-grade gliomas.J Neurooncol2021
33691798Differentiating IDH status in human gliomas using machine learning and multiparametric MR/PET.Cancer Imaging2021
34121166Worse prognosis for IDH wild-type diffuse gliomas with larger residual biological tumor burden.Ann Nucl Med2021
33106922Relative oxygen extraction fraction (rOEF) MR imaging reveals higher hypoxia in human epidermal growth factor receptor (EGFR) amplified compared with non-amplified gliomas.Neuroradiology2021
33359353Using non-invasive neuroimaging to enhance the care, well-being and experimental outcomes of laboratory non-human primates (monkeys).Neuroimage2021
30659892Longitudinal MRI findings in patients with newly diagnosed glioblastoma after intraoperative radiotherapy.J Neuroradiol2020
32365185Diffusion Magnetic Resonance Imaging Phenotypes Predict Overall Survival Benefit From Bevacizumab or Surgery in Recurrent Glioblastoma With Large Tumor Burden.Neurosurgery2020
32239430Diffusion MRI changes in the anterior subventricular zone following chemoradiation in glioblastoma with posterior ventricular involvement.J Neurooncol2020
31981013Rate of change in maximum <sup>18</sup>F-FDOPA PET uptake and non-enhancing tumor volume predict malignant transformation and overall survival in low-grade gliomas.J Neurooncol2020
32929644Multiparametric MR-PET measurements in hypermetabolic regions reflect differences in molecular status and tumor grade in treatment-naïve diffuse gliomas.J Neurooncol2020
32582544The MRI Features and Prognosis of Gliomas Associated With IDH1 Mutation: A Single Center Study in Southwest China.Front Oncol2020
32861192Glioblastoma Utilizes Fatty Acids and Ketone Bodies for Growth Allowing Progression during Ketogenic Diet Therapy.iScience2020
32681084Human IDH mutant 1p/19q co-deleted gliomas have low tumor acidity as evidenced by molecular MRI and PET: a retrospective study.Sci Rep2020
32908231Decorin expression is associated with predictive diffusion MR phenotypes of anti-VEGF efficacy in glioblastoma.Sci Rep2020
31437274Imaging challenges of immunotherapy and targeted therapy in patients with brain metastases: response, progression, and pseudoprogression.Neuro Oncol2020
30659892Longitudinal MRI findings in patients with newly diagnosed glioblastoma after intraoperative radiotherapy.J Neuroradiol2020
31981013Rate of change in maximum <sup>18</sup>F-FDOPA PET uptake and non-enhancing tumor volume predict malignant transformation and overall survival in low-grade gliomas.J Neurooncol2020
32861192Glioblastoma Utilizes Fatty Acids and Ketone Bodies for Growth Allowing Progression during Ketogenic Diet Therapy.iScience2020
32681084Human IDH mutant 1p/19q co-deleted gliomas have low tumor acidity as evidenced by molecular MRI and PET: a retrospective study.Sci Rep2020
32908231Decorin expression is associated with predictive diffusion MR phenotypes of anti-VEGF efficacy in glioblastoma.Sci Rep2020
32929644Multiparametric MR-PET measurements in hypermetabolic regions reflect differences in molecular status and tumor grade in treatment-naïve diffuse gliomas.J Neurooncol2020
  • 1 - 50 of 334

Recommended Authors

Barbara Kiesel
Medical University of Vienna
Career Start Year 2012
Number of shared co-authors 2
Johannes Kerschbaumer
Medical University of Innsbruck
Career Start Year 2012
Number of shared co-authors 1
Vaios Hatzoglou
Memorial Sloan Kettering Cancer Center
Career Start Year 2011
Number of shared co-authors 0
Christian F Freyschlag
Medical University of Innsbruck
Career Start Year 2010
Number of shared co-authors 1
Julia Furtner
Medical University of Vienna
Career Start Year 2009
Number of shared co-authors 5
Martha Nowosielski
Medical University of Innsbruck
Career Start Year 2009
Number of shared co-authors 6
Rohan Ramakrishna
Weill Cornell Medical College, New York Presbyterian Hospital
Career Start Year 2009
Number of shared co-authors 7
Adelheid Woehrer
Medical University of Vienna
Career Start Year 2008
Number of shared co-authors 5
Kyrre E Emblem
Oslo University Hospital
Career Start Year 2008
Number of shared co-authors 2
Benedikt Wiestler
Technical University
Career Start Year 2007
Number of shared co-authors 8
Joanna J Phillips
University of California san francisco
Career Start Year 2006
Number of shared co-authors 10
Sherise D Ferguson
The University of Texas MD Anderson Cancer Center
Career Start Year 2005
Number of shared co-authors 4
Nancy Ann Oberheim Bush
University of California san francisco
Career Start Year 2005
Number of shared co-authors 3
Joost J C Verhoeff
University Medical Center Utrecht
Career Start Year 2005
Number of shared co-authors 0
Seung Hong Choi
Seoul National University Hospital
Career Start Year 2003
Number of shared co-authors 2
Gelareh Zadeh
University of Toronto
Career Start Year 2003
Number of shared co-authors 16
Thomas J Kaley
Memorial Sloan Kettering Cancer Center
Career Start Year 2003
Number of shared co-authors 14
Martin Glas
University Hospital Essen
Career Start Year 2002
Number of shared co-authors 3
Marco Skardelly
University Hospital Tubingen, Eberhard-Karls-University Tubingen
Career Start Year 2002
Number of shared co-authors 1
Ichiyo Shibahara
Kitasato University School of Medicine
Career Start Year 2002
Number of shared co-authors 3
Andrew P Morokoff
Clinical Sciences Building, The University of Melbourne, The Royal Melbourne Hospital
Career Start Year 2001
Number of shared co-authors 2
Thomas Roetzer
Medical University of Vienna
Career Start Year 2000
Number of shared co-authors 1
Chul-Kee Park
College of Medicine, Seoul National University
Career Start Year 2000
Number of shared co-authors 4
Ghazaleh Tabatabai
University Hospital Tubingen, Eberhard-Karls-University Tubingen
Career Start Year 1998
Number of shared co-authors 9
Clark C Chen
University of Minnesota
Career Start Year 1994
Number of shared co-authors 10
Ganesh Rao
The University of Texas M.D. Anderson Cancer Center
Career Start Year 1994
Number of shared co-authors 8
Georg Widhalm
Medical University of Vienna
Career Start Year 1988
Number of shared co-authors 6
Camilo E Fadul
University of Virginia Health System
Career Start Year 1987
Number of shared co-authors 2
Javier E Villanueva-Meyer
University of California san francisco
Career Start Year 1986
Number of shared co-authors 9
Mitchel S Berger
University of California san francisco
Career Start Year 1982
Number of shared co-authors 20

Collaborators

Timothy F Cloughesy
David Geffen School of Medicine, University of California Los Angeles
Co-authored papers 104
Benjamin M Ellingson
David Geffen School of Medicine, University of California Los Angeles
Co-authored papers 97
Noriko Salamon
David Geffen School of Medicine, University of California Los Angeles
Co-authored papers 33
Paul S Mischel
Stanford University
Co-authored papers 16
Patrick Y Wen
Co-authored papers 11
Joe Qiao
University of California los angeles
Co-authored papers 10
Johannes Czernin
university of california los angeles
Co-authored papers 10
Jonathan G Goldin
David Geffen School of Medicine at university of california los angeles
Co-authored papers 7
Raymond Y Huang
Brigham and Women's Hospital, Harvard Medical School
Co-authored papers 6
Juan Pablo Villablanca
David Geffen School of Medicine, University of California Los Angeles
Co-authored papers 6
Michael Weller
University Hospital and University of Zurich
Co-authored papers 6
Danny J J Wang
Stevens Neuroimaging and Informatics Institute, University of Southern California
Co-authored papers 5
Stanley F Nelson
university of california los angeles
Co-authored papers 5
Warren P Mason
Princess Margaret Cancer Centre
Co-authored papers 4
Matthew S Brown
University of California los angeles
Co-authored papers 4
Kambiz Nael
David Geffen School of Medicine, University of California Los Angeles
Co-authored papers 4
Daniel H S Silverman
University of California los angeles
Co-authored papers 4
Michael D Prados
University of California san francisco
Co-authored papers 4
Wai-Kwan Alfred Yung
University of Texas M.D. Anderson Cancer Center
Co-authored papers 3
James Sayre
David Geffen School of Medicine at university of california los angeles
Co-authored papers 3
Michael A Vogelbaum
Moffit Cancer Center
Co-authored papers 3
Tom Mikkelsen
Ontario Brain Institute
Co-authored papers 2
Jeffrey L Saver
Ronald Reagan university of california los angeles Medical Center
Co-authored papers 2
Josep Garcia
Co-authored papers 2
Tracy T Batchelor
Brigham and Women's Hospital
Co-authored papers 2
John F de Groot
Co-authored papers 2
Rivka R Colen
Co-authored papers 2
Soonmee Cha
Co-authored papers 2
David Schiff
University of Virginia School of Medicine
Co-authored papers 2
David S Liebeskind
University of California Los Angeles (D.S.L.).
Co-authored papers 2
Release 1.2